Delcath Systems Inc (DCTH)

[Looking4BIGcash]

DELCATH SYSTEMS, INC.
FORM 8-K
(Current report filing)
Filed 01/26/18 for the Period Ending 01/25/18
Address
1633 BROADWAY
SUITE 22C
NEW YORK, NY, 10019
Telephone
[phone]
CIK
0000872912
Symbol
DCTH
SIC Code
3841 - Surgical and Medical Instruments and Apparatus
Industry
Medical Equipment, Supplies & Distribution
Sector
Healthcare
Fiscal Year
12/31
http://www.edgar-online.com
© Copyright 2018, EDGAR Online, a division of Donnelley Financial Solutions. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, a division of Donnelley Financial Solutions, Terms of Use.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 25, 2018
DELCATH SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-16133
06-1245881
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
1633 Broadway, Suite 22C, New York, New York
10019
(Address of principal executive offices)
(Zip code)
[phone]
(Registrant’s telephone number, including area code)
None
(Former name or
former address, if changed since last report.)
Check the appropriate box below
if
the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (
see
General Instruction A.2
below):
?
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
?
Soliciting material pursuant
to Rule 14a-12 under the
Exchange Act
(17 CFR 240.14a-12)
?
Pre-commencement communications pursuant
to Rule 14d-2(b) under the
Exchange Act
(17 CFR 240.14d-2(b))
?
Pre-commencement communications pursuant
to Rule 13e-4(c) under the
Exchange Act
(17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the
Securities Exchange Act
of 1934 (§240.12b-2 of this
chapter).
?
Emerging growth company
?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to
section 13(a) of the Exchange Act.
Item 8.01
Other Information
On December 28, 2017, we entered into exchange agreements
(collectively, “Exchange Agreements”), each by and between us and an investor from our June
2016 private placement of senior secured convertible notes (as further exchanged, the “Notes”) originally issued pursuant to that certain
Securities Purchase
Agreement, dated June 6, 2016, by and among us and such investors. Pursuant to the Exchange Agreements, we, among other things, issued to the investors shares
(the “Shares”) of our common stock (or rights
(“Rights”) to receive common stock to the extent such issuance of Shares would otherwise result in the beneficial
ownership by any such investor of more than 4.9% or 9.9% of our issued and outstanding stock), as applicable, of an aggregate
of 123,708,735 shares of our
common stock. As of January 25, 2018, all of the Rights have been exercised, and neither investor owns more than 4.9% of the issued and outstanding shares of our
common stock. Since the Notes have been satisfied in
full as a result of the Exchange Agreements, there is no longer a security interest in our assets with respect to
the Notes. As of January 25, 2018, we had 222,981,824 shares of our common stock issued and outstanding.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
DELCATH SYSTEMS, INC.
Date: January 26, 2018
By:
/s/ Jennifer Simpson
Name:
Jennifer Simpson
Title:
President and Chief Executive Off